logo-loader
viewCircassia Pharmaceuticals PLC

Circassia Pharmaceuticals study data published in leading medical journal

The ASCENT phase IV study assessed the potential of the company's drug Tudorza to treat moderate-to-very severe chronic obstructive pulmonary disease

tudorza inhaler
The data showed the inhaled powder was effective at combating exacerbations (worsening of the symptoms) of COPD with no increase in major cardiovascular events

Circassia Pharmaceuticals PLC (LON:CIR) said findings from a recent clinical trial of one of its key drugs will appear in a prestigious scientific publication.

The Journal of the American Medical Association will carry the results from the ASCENT phase IV study, which assessed the potential of Tudorza to treat moderate-to-very severe chronic obstructive pulmonary disease (COPD).

The data showed the inhaled powder was effective at combating exacerbations (worsening of the symptoms) of COPD with no increase in major cardiovascular events.

Heart disease often goes hand in hand with COPD and 30% of patients die as a result of related conditions.

The phase IV trial provided what’s called a label extension for Tudorza, which means the drug can be administered to a wider patient group.

Circassia chief executive Steve Harris said: "The publication of these clinical results in the prestigious Journal of the American Medical Association further demonstrates Tudorza's safety and efficacy, particularly in this group of at-risk patients. 

“We are delighted at this recognition of the importance of these data, and of the recent inclusion of this new information in Tudorza's prescribing information."

Quick facts: Circassia Pharmaceuticals PLC

Price: 17.6 GBX

LSE:CIR
Market: LSE
Market Cap: £66.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read